Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
question is WHEN certainly not next year. buy/hold the dip till homeless.
You're getting old year by year. Maybe you won't be able to see NWBO unblinding. People need a lifetime for them to see nwbo unblinding
Cool down man, don't get a stroke getting so worked up. If you have no faith in this company at all, just short the crap out and you will feel better. I will take the opposite side of your trade.
With Cognate locking up 15% of the shares the shorts can't short those any longer. Don't care if LP does some legal maneuvers to keep the company running til approval.
We'll see who has the last laugh.
Lol don't you get it? The spike was due to financing and speculation on the result. Now that we only heard is just financing what makes u think it will hold .20+ or even .18 it will stay around .17 or lower most likely mm are in control again. speculators are going off the boat and dont get back until prophets make another assumption on when nwbo will uncover AGAIN. Ive been hearing result around the corner since 2016 and its about to enter 2018 people still believe them thats its gonna be few more months LOL.
Take advantage because it will be short lived.
I would put buy orders from 18 up with 0.5 or 1 cent increment. I see a shakeout coming and it will be fast - a dip and a key reversal. The MMS will take it down once more just watch the action today and the fake offers to cap buys.
Yes but what are the terms? That is what the argument will be about. Not if the merge or not. NWBO has paid for the technology and facilities.
A typical contract manufacturer gets 15 to 25% of revenue. So at this point, what will be the terms.
Maybe it could even test 0.21 today
So you could buy back? Don't scrimp on a couple of cents and miss the boat. It may hit 20 but it could be so fast and revert before you can say wait - unless you have a standing order and there's no guarantee. We hit 22 twice today in a blink.
A merger would put all this AP between the two companies to rest. I sincerely believe it will happen in due time now that LP has regained control. Not only would this boost the PPS as a result of the combined entity, NWBO would be an operating company that would be more attractive to any potential bidder. At the moment this setup is purely a defensive move.
chris's link still not working for me. another link?
I am listening to it now!
I just bought some this morning and will do again next week. That's interesting too! Happy Thursday
Les is a yes man and the sun is out when it is raining. I do agree with you about contacting the company. I did email them today and said now you manufacturing paid and built out and your employees are taken care of though most are family. What about letting you investors what is happening with the company Publication, interim, DCVAXIII. The company has a fiduciary duty to keep their investors informed without us there would be no financing. So I do encourage investor to get intouch and not let them carry this over 1 more year without update!!!
Give it up there is no way the FDA even thinks about this company. Why would they trust the worst CEO in Biotech? Haha this trial will go on forever
The price action today is very very interesting!
Chris did you listen? the link no longer works
When I read this post I thought to myself that we probably had not finished dropping. Which would make your statement moot.
A few more months Interim blinded data. PFS and OS reached Publication. Lots of dilution. Why not good news today? Why wait? IMHO
Here is the thing. If the parameters have changed from going to (aka: having gone to) data lock at about 233OS, and those changed time parameters were shared via NDA with preferred investors and not common investors, then we have a bifurcation of information with the latter being set adrift upon relying on old info. As time goes on, and dilution mounts, those fortuitous preferred investors entered at the "bottom" although the bottom was nowhere to be found when they entered (aka: the door was held open), it too was also past. In other words, common retail is basically receiving what deletion of net neutrality will look like someday. Old worthless and therefore potentially detrimental data. Or as Bill Murray might say in Scrooged, retail was "scraped off."
If NWBO has not changed the time parameters, then it is likely there could be either public release of topline data at any time, or perhaps FDA processing is ongoing. and public release is being withheld for the time being.
Providing two opposing sets of expectations for two very different investor groups is not what I would expect.
IMHO.
Looks like Sojo was correct, probably test .21 soon. MACD cross two days ago, DMI convergence and approaching 50 day EMA support. Let's see what it does from there. News needed.
Cognate's been paid 10's of millions by NWBO. There are other contracts they've signed with customers I've heard. But I'm believing that those were insignificant in comparison.
https://www.help.senate.gov/hearings/implementation-of-the-21st-century-cures-act-progress-and-the-path-forward-for-medical-innovation
Gottlieb speaking now on 21st century cures act
Read the one about the injections and the trial configuration the one before last
I read it and it doesn't say it.
The bylaws require an ASM announcement by tomorrow. imo. It looks like they will share that scheduling on Friday. If not, they are late, but Ex says a late ASM is not the end of the world.
These are my thoughts. Further more if Cognate is using NWBO assets in anyway they would owe money to NWBO. IMHO
IMO, unless Cognate can show significant revenues from any or all non NWBO sources. NWBO owns Cognate and all of its assets. I would want a shareholder lawsuit to this fact. Obviously in a single company set up NWBO would have all those assets, clean rooms, buildings, etc. As evidenced by the recent NWBO financings to include benefits for Cognate employees. Which for all intents and purposes are NWBO employees.
There isn't going to be any science if you do not vote to help them raise the money needed to finish the trial.
It is hard and I will not argue to defend NWBO communication strategy. I would advise all shareholders to call Les Goldman and voice their concerns (probably again) about the lack of current status info on the study. I believe Cognate had to be paid and I am personally fine to square them up as they have as either way us shareholders would have been diluted. I was surprised they went the full distance they did with the Cognate deal but I believe it was seen as a necessity to maintain control to enable them to extract value. This has been a long term situation and though in the last lap of the first phase there is apparently a little more time to pass here. I thought Nov to Jan at the latest we would see data. Now I am hopeful to see the publication in that time frame and data to come shortly after (up to 3 mos). We have no way to know whether the publication will be strong enough evidence to demonstrate unprecedented effectivity since stats will probably not be in abundance and actual median difference will not be the lion's share of the benefit of DCVax-L. It is possible survivor rates would also be shown and that can be the holy grail here. Lastly I would say that if they have been silent through the last 2 years and if now is the pinnacle of data sensitivity and hopefully regulatory pathway discussions, I would hold little hope of new, more open communications now. This is the time that all companies hold back more as required by the situation. Even when you get communications from companies at this stage it can be very frustratingly vague. I follow another company who is steeped in regulatory issues and their words are so carefully chosen that only if you have worked in a regulatory function would you even think you have a sense of what they are trying to say and not say.
I agree that the company communications is not a comfortable strategy for shareholders. I will vote yes but would strongly prefer more open communications and always have preferred that despite the fraudulent AF activity. However the company chose another communication strategy, but, I am still a shareholder who has chosen to avg down as well, believing in the science and in NWBO management's resolve.
Practically... key word in that sentence.
But in reality does not say it.
Whats a Q10 anyways? lmao
prac·ti·cal·ly
'prakt?k(?)le/
adverb
adverb: practically
1.
virtually; almost.
"the risk of default was practically zero"
synonyms: almost, (very) nearly, virtually, just about, all but, more or less, as good as, to all intents and purposes, verging on, bordering on; More
informalpretty near, pretty well;
literarywell-nigh
"the theater was practically empty"
2.
in a practical manner.
synonyms: realistically, sensibly, reasonably
"“You can't afford it,” he pointed out practically"
Read the Q10 it practically says it
That would be fine if we knew that was what happening but we are told nothing. She could use that money to continue building out the manufacturing which has no effect on the stock. It all belongs to cognate.So what good does the do for the investors. They need to tell what is happening where is the Publication, interim, DCVAX-L progress, OS just anything but no the silence has increased and all we get is financing PR.
All those recent "friendly" funds/guys have signed NDAs and yet they got $0.17 shares plus $0.22 warrants.
What on earth did that imply "a winning card" is near or in hand? Or if that's true, meaning we will see a successful trial result in the near future, then how horrendous was the financing deal we just had, or how absurd we have been sold by dear leader Linda Power!
Come on, I give the chance of eventual success at 65%, but Linda has to be watched, and reported for her suspicious action.
Personally, I believe she has enriched herself on an ongoing basis, even now under SEC's watch (BTW, SEC is nothing of a strawman anyhow, set it up to protect big money, not retail investors.)
There is a myth saying voting no will bankrupt the company. Well, voting yes will bankrupt the company too on the same argument that if the trial is a failure! On the other hand, even if the trial is a failure, the company can still continue as a business with R/S, dirty/cheap deals with financiers (old or new),etc.
There even is case where a company announced bankruptcy because of FDA rejection to its drug application for approval (thus it could not raise any fund to continue), but a few months later it was revived and soaring after FDA reconsidered its previous decision.
I was lucky enough to participate in another company (VNDA) when its largest shareholders asked the court to liquidate the company, in a similar circumstance where its drug was rejected by FDA and the only thing it could do was to appeal. I got in at around $0.9, and got out at around $8 ~ 12 after FDA reversed its own decision.
Realistically, I don't think at the point our no votes will make any concrete difference as Linda has already made those "retail investors despising move to secure enough votes for whatever she wants to do; during this process she has sold us retail investors, but a no vote can send a message to her that we are not happy, and be aware.
There may be further action if necessary!
Because there is cross over confoundment, the trial being originally designed as a phase 2,it became a P3 with no technical changes I believe the FDA have requested a specific amount of long tail data hence the reason the trial will run three from last vaccination so all being said,no data has been unblinded and is unlikely to be until November 2018 so you have a long long wait and probably another billion shares of dilution before you hear.Not great news but it provides you with a sense of reality.I will be on the sidelines until mid to
Later part of next year to pick the bones of the carcass.Please learn not to discuss conferences and don't fall for the 2028 ASCO BS because it won't happen there
Whether this is true or not I for one has made my decision if asked to vote. We should all be able to do that without being pressured. I chose to believe that any adult that has invested in this company is intelligent enough to conduct sufficient DD on all matters relating to such matters. I will be voting yes as I have stated however I can definately see how the company's failings regarding their communications (which you have noted yourself) could cause a negative vote by many. I personally think it will not stop the yes vote but the company could improve their communications with shareholders anytime it suits them.
Those drugs activate STING in multiple cells within the tumour microenvironment after being injected into a lesion. The innate response involves cytolytic activity from TNFa, activated neutrophils and repolarises M2 macrophages into M1's. The adaptive response is dependent on certain type I interferons and STING activation in dendritic cell subsets (Batf3+). Abscopal effects are via polyfunctional tumour antigen specific T-cells http://www.cell.com/cell-reports/fulltext/S2211-1247(15)00432-5 http://www.tandfonline.com/doi/full/10.1080/2162402X.2017.1346765
Assuming the latter happens then patients should become candidates for certain CI's, IDO inhibitors https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136707/ and maybe other drugs that target Tregs https://www.jci.org/articles/view/64859 http://www.cell.com/immunity/fulltext/S1074-7613(17)30123-1
Followers
|
1620
|
Posters
|
|
Posts (Today)
|
184
|
Posts (Total)
|
689582
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |